• Coyuchi guarantees the highest environmental and ethical standards through a number of certifications, such as The Global Organic Textile Standard (“GOTS”), Fair Trade Certified, and MADE SAFE(R)
• The global organic bedding market was valued at $836.4 million in 2020 and is expected to reach $1.1 billion by 2025, growing at a CAGR of 5.1%
• Coyuchi was built on foundational pillars, all successfully molded into a proven and effective marketing strategy, earning Coyuchi $33.3 million in net sales during 2021 with a 35% average customer repeat rate

Coyuchi, the gold standard in sustainable luxury home goods, is best known for using 100% organic cotton materials in the textiles it produces. The company’s sustainably produced products include luxury organic bedding, sheets, towels, apparel, and other home goods that cater specifically to homes focused on environmental consciousness. Not only does Coyuchi offer something for every home, but it also offers something for every family member, including the newest bundles of joy.

Organic cotton is grown naturally and sustainably without using herbicides, pesticides, or other harmful chemicals, which can irritate a baby’s sensitive skin. Made only with safe, non-toxic materials, Coyuchi’s certified organic products are gentle enough for use from the moment a new baby enters the world. Coyuchi’s line of organic baby products includes blankets, sheets, and wother shower gifts that are gentle on the baby and the environment.

The global organic bedding market was valued at $836.4 million in 2020 and is expected to reach $1.1 billion by 2025, growing at a CAGR of 5.1%. This growth is supported by the shifting consumer preference for high-end lifestyle products and the rising prominence toward products manufactured with sustainability and durability in mind (https://ibn.fm/KrAC2). Not only does organic bedding benefit adult consumers, but the luxurious and soft, chemical-free production is also preferred for babies – making it safe for all ages.

Coyuchi continues pushing the organic textile market forward through its circular initiatives and supporting cross-industry sustainability advocates:

• Circular business model – Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change through its take back and recycling program, 2nd Home(TM).
• Coyuchi Climate Council – In early 2022, the company introduced a cross-disciplinary council with the goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030.
• C4: The California Cotton & Climate Coalition – Coyuchi’s most recent announcement is becoming a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. C4 creates a structure for investing in regionally grown, Climate Beneficial(TM) cotton that directly supports the livelihoods of the farmers that grew it.

The company was built on four foundational pillars:

• protect the planet
• innovate circular design
• live sustainably
• enrich the community

These principles are integrated into a proven and effective marketing strategy, earning Coyuchi $33.3 million in net sales during 2021 with a 35% average customer repeat rate.

For 30 years, Coyuchi has explored organic farming and sustainable textiles, guaranteeing the highest environmental and ethical standards through a number of certifications, such as The Global Organic Textile Standard (“GOTS”), Fair Trade Certified, and MADE SAFE(R). Coyuchi’s mission is to bring beauty and comfort to every home without sacrificing the planet’s health.

Coyuchi is currently accepting investment as part of a Regulation A+ offering. Manhattan Street Capital is handling the investment opportunities for Coyuchi, and more information can be found on their website (https://ibn.fm/wUu87).

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• Silo Pharma recently provided an update on an ongoing study delving into the potential use of SP-26 as an alternative treatment for fibromyalgia
• The study, which is being carried out in conjunction with Experimur, has looked into the feasibility of using a time-released, dosage-controlled formulation of ketamine as a suitable treatment for the chronic medical condition
• Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had achieved a positive outcome for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. The results come after Silo Pharma had previously revealed that it was working on the preparation of a pre-Investigational New Drug (“IND”) package and meeting request with the US Food and Drug Administration (“FDA”) for a novel formulation of ketamine destined towards the treatment of fibromyalgia (https://ibn.fm/X5GM4).

At the time, Eric Weisblum, Silo Pharma’s Chief Executive Officer had remarked on the company’s efforts, “We are confident that our highly constructive pre-clinical work on SP-26 will offer strong support for our pre-IND package as we seek to advance our time-released ketamine delivery system into the clinic” (https://ibn.fm/tHFlD).

Fibromyalgia is a chronic condition causing pain to the connective tissues through the body including muscles, ligaments and tendons. Musculoskeletal pain is often accompanied by sleep difficulties, fatigue, mood disorders and problems with memory and concentration. Despite having over four million Americans living with fibromyalgia, there is relatively little known about this condition, and no apparent physical cause has been identified thus far. As of 2020, the FDA had approved three drugs specifically for treating fibromyalgia, however these have primarily been destined towards the treatment of specific symptoms, such as depression or nerve pain, rather than acting as a more holistic treatment (https://ibn.fm/k1mMN).

Now and in collaboration with Experimur, a Frontage Laboratories company, Silo Pharma have provided an update as to their efforts in producing a ketamine-based treatment for fibromyalgia. The company detailed in a recent announcement that it had tested SP-26 in a toxicology and tolerability study in mini pigs using an ascending (descending) dosing regimen. The study was carried out in adherence to the bioanalytical methods required to perform toxicology studies by the U.S. Food and Drug Administration (“FDA”) in advance of initiating clinical studies for SP-26.

“Today’s positive results are an important step as we move closer to achieving all needed components to plan human trials of SP-26.” remarked Weisblum. “We are advancing our work with our regulatory partners to prepare a Pre-Investigational New Drug (‘IND’) package for SP-26 and intend to pursue the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval.”

Originally founded in 2010, Silo Pharma has rapidly earned a reputation in recent years for its ground-breaking research into conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. In addition to its recent research into potential fibromyalgia treatment alternatives, Silo Pharma have also been involved in a number of studies designed to develop innovative solutions for previously underserved conditions, including exploring the use of a prophylactic treatment for drug-resistant depression and delving into the effects of psilocybin on inflammation, among several other initiatives.

For more information, visit the company’s website at www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• Ucore Rare Metals Inc. is a Canada-headquartered company passionate about strengthening North America’s rare earth element (“REE”) supply chain to reduce reliance on potentially adversarial foreign nations
• Rare earths play small but critical roles in high-tech products, such as in making up permanent magnets that are resistant to heat from high capacity electronic products
• Only one mine in California provides a domestic supply of REEs to the United States, which has netted it strategic financial support from the Pentagon
• Ucore recently completed the first stage of demonstrating its proprietary RapidSX(TM) solvent extraction process for improving REE production, inviting dozens of industry and government visitors to witness its effectiveness at a Demo Plant in Canada
• The company plans to use the process in a Louisiana commercial-scale processing facility, which will begin construction later this year to provide a planned 2,000 metric tons of total rare earth oxides (“TREOs”) production by early 2025

Critical metals production tech innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) has completed the first stage of an ambitious strategy to help disrupt the People’s Republic of China’s control of the North American rare earth element (“REE”) supply chain, welcoming dozens of industry and government visitors for a demonstration of its proprietary RapidSX(TM) REE separation process, according to a March 16 news release.

Ucore Rare Metals hosted private tours and demonstrations of the operational advantages RapidSX’s(TM) 52-stage REE separation processing system in early March at the company’s Ontario, Canada-based Commercialization and Demonstration Facility (“CDF”), the news release states (https://ibn.fm/DuHiu). The company anticipates putting the RapidSX(TM) process to work on a commercial scale at its first Strategic Metals Complex (“SMC”) in Louisiana, in the southern United States, which will begin construction later this year.

Rare earth elements are metallic elements that perform small but vital functions in current high-tech electronic devices such as cell phones, computer hard drives and TVs, as well as a number of government defense products. They occur within ores and are separated from ore by an SX solvent extraction process used worldwide, but Ucore anticipates developing RapidSX(TM) as a widely used process that is faster and ultimately cheaper.

China established an overwhelming dominance in the REE market long ago and has demonstrated a willingness to leverage its market control during international disputes, cutting off adversaries’ access to the tech metals (or threatening to do so) such as when Japan was restricted in 2010 during a boundary dispute over the East China Sea (https://ibn.fm/ouEVv).

California’s Mountain Pass mine, owned by MP Materials, is currently the only operating rare earth mine and processing facility in the United States and concerns about North America’s vulnerability to China’s control of the REE market have prompted Ucore to present its solution as a way to improve Western Hemisphere processing of the ores. 

Ucore will add to its Louisiana SMC with additional SMC processing facilities in Alaska and Canada, and the company also has a 100 percent ownership stake in a rare earth mine prospect in Alaska that it eventually plans to develop as a North American source for REEs.

The mine holds more than 4.7 million metric tons of indicated rare earth ore, which amounts to about 63.5 million pounds of collective rare earth metals (https://ibn.fm/CUqnF).

The Louisiana brownfield SMC is scheduled to begin processing 2,000 metric tons of total rare earth oxides (“TREOs”) annually by early 2025, and the company expects to increase its TREO supply chain capacity to 5,000 metric tons by 2026.

Ucore’s success in the first phase of extraction circuit testing at the Ontario demonstration facility was designed to separate heavy REE (“HREE”) from light REE (“LREE”), and once the Demo Plant there is fully commissioned it will process “tens of tonnes of North American-friendly sources of mixed rare earth chemical concentrates” in an environment that simulates commercial production, according to the company.

The plant’s output will be high-purity Neodymium-Praseodymium (“NdPr”) used in permanent magnets for tech products including electric vehicle drive trains, as well as praseodymium, neodymium, terbium and dysprosium REEs.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• CISO achieves SOC 2 Type II certification following annual audit
• President says company is committed to building relationships of trust with clients
• Achieving certification symbolizes commitment to safeguarding customers’ data

As an industry leader in global cybersecurity and compliance services, CISO Global (NASDAQ: CISO), formerly Cerberus Cyber Sentinel Corp., recently reached a significant milestone (https://ibn.fm/BNFYO). The company announced that it has achieved SOC 2(R) Type II certification following its annual SOC 2 Type II audit.

“We believe that the relationship with our clients must be built on trust,” said Ashley Devoto, president and chief information security officer of Cerberus Sentinel. “As companies increase their usage of vendors and partners to perform activities that are core to their business operations and strategies, there is a need for the highest level of confidence and transparency into service providers’ abilities to safeguard customer data.”

Achieving the SOC 2 Type II certification, which was confirmed by an independent audit, is symbolic of Cerberus Sentinel’s commitment to providing the highest level of protection and honoring clients’ trust. The certification validates that Cerberus security controls and data-privacy practices meet best practices.

Cerberus Sentinel continues to strengthen its reputation as a managed cybersecurity and compliance provider that can be trusted to secure its customers’ systems. The SOC 2 Type II certification is widely recognized as a symbol of trust and excellence. This certification involves an in-depth review of controls relevant to security, availability, processing integrity, confidentiality and privacy and provides compliance attestation for service providers worldwide.

Typically, a SOC 2 audit is performed by an accredited CPA firm in accordance with the American Institute of Certified Public Accountants’ (“AICPA”) AT-C 205, “Reporting on Controls at a Service Organization,” and is based on the trust service principles outlined in the AICPA Guide “Reporting on Controls at a Service Organization Relevant to Security, Availability, Processing Integrity, Confidentiality, or Privacy.” The company noted that “achieving this standard with an unqualified opinion serves as third-party industry validation that Cerberus Sentinel manages customers’ data with the highest standard of security and compliance.”

Cerberus Sentinel is an industry leader in its role as a global cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations, mitigating continuing and emerging security threats and compliance obligations.

For more information, visit the company’s website at www.CISO.Inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• Food waste contributed 9.3 billion metric tons of CO2-equivalent emissions in 2017, an amount equal to the total emission from the U.S. and E.U. that year
• EverGen Infrastructure is a leading independent renewable energy producer with operations and a platform for converting organic waste in green energy and products
• EverGen’s Sea to Sky Soils signed waste processing contracts with a B.C. regional district, an important step towards a goal of processing 300,000 tons of organic waste per annum in the region

There is finger pointing everywhere to single-out culprits in climate change, and exhaust-spewing fossil fuel-powered cars are an easy target. The reality is that, while it may sound great in theory, simply replacing all the cars on the road with electric alternatives carries several challenges related to infrastructure and battery materials. While the EV transition should remain a focus to address hurdles, an emphasis on responsible waste management can have an immediate impact on decarbonization.

Waste-to-energy technologies, such as those of EverGen Infrastructure’s (TSX.V: EVGN) (OTCQX: EVGIF), are in use today, reducing dependence on finite fossil fuels and putting would-be trash to good use in a green manner. EverGen, known as Canada’s Renewable Natural Gas Infrastructure Platform, is an established independent renewable energy producer which acquires, develops, builds, owns, and operates a portfolio of Renewable Natural Gas (“RNG”), waste to energy, and related infrastructure projects.

RNG is a carbon-neutral fuel that can be produced from multiple organic feedstocks, including food and animal waste and wastewater, that is processed in an anaerobic digester into products such as fertilizer and soil amendments or a biogas that is further refined to be an essentially identical replacement for conventional natural gas.

EverGen designs and builds the system and facilities, collecting organic feedstock from its partners, such as municipalities and farms. The RNG output can be used locally or sold to utilities – for instance, EverGen has several agreements with FortisBC – where the RNG is fed into the existing natural gas pipeline. At its Sea to Sky Soils facility in British Columbia, EverGen keeps organic waste out of landfills by turning it into high-quality soil amendments and blends for use on farms, gardens, and landscapes.

The adoption of these type of systems is critical as waste is mushrooming worldwide and contributing to Earth’s rising temperature. According to the U.N. Food and Agriculture Organization, about one-third of all food produced annually is either lost or wasted. In 2017, global food wasted contributed 9.3 billion metric tons of carbon dioxide-equivalent emissions. To put that in perspective, that was roughly the same amount at the total combined emissions of the U.S. and E.U. in 2017.

A study published this month on Nature.com reiterated the need for better cradle-to-grave food management, noting that emissions from food loss and waste represent half of total greenhouse gas emissions from food systems.

On February 21, EverGen announced its Sea to Sky Soils business signed multiple contracts with a British Columbia regional district for the processing of organic waste at the facility, which provide for over 10,000 tons per annum. A steward to the local community, Sea to Sky Soils is operated in partnership with Lil’wat First Nation.

According to EverGen CEO Chase Edgelow, the latest contracts are “another step towards our goal of providing solutions for over 300,000 tonnes of organic waste per annum in the region.”

The company also owns Net Zero Waste Abbotsford and Frasier Valley Biogas in British Columbia and in 2022 began its expansion east across Canada with projects in Alberta and Ontario.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• SideChannel is focused on providing top-tier security guidance services at manageable cost through its team of expert vCISOs and vCPOs
• The company’s experts provide clients with risk assessments that ensure cybersecurity compliance and guide them in the development of effective cybersecurity programs
• Most corporate board members and top managers do not have cyber-related expertise, yet they are required to oversee and address their company’s cyber risks
• To bridge the information gap, boards and management need the guidance of security experts such as CISOs
• Through its team of vCISOs, SideChannel is providing affordable cybersecurity-oriented services that meet the critical needs of company management and boards

A large proportion of company board members, as well as managers, are not cyber experts, yet they are mandated to understand and make strategic decisions regarding cyber risk and solutions. In particular, various studies have revealed low confidence levels in the ability of boardroom directors to fully be aware of a company’s cybersecurity vulnerabilities. For instance, a 2022 PwC study noted that only 33% of directors feel their board truly understands the company’s cybersecurity vulnerabilities (https://ibn.fm/C59KD). Similarly, a recent WSJ Pro Cybersecurity Research report found that only 30% of directors rate their board’s ability to oversee a cyber crisis highly (https://ibn.fm/knIH0).

Boards, together with high level management, can nevertheless improve their abilities to recognize and address cyber risks. To achieve this, board members need access to security expertise, along with robust information and reporting, and active engagement with company leadership. Moreover, company boards need to better support their organizations in establishing effective cybersecurity risk management programs, according to the findings of the PwC report.

The report lays out four main proposals intended to help boards better undertake their cyber risk oversight role: ensure cyber risk is embedded in the company’s strategic decisions and culture; understand the cyber risk management program; monitor cyber resilience; and rethink the board’s cyber oversight approach. Central to the effectiveness and success of these proposals is the role of Chief Information Security Officers (“CISOs”).

For instance, the report recommends that CISOs should have a seat at the table whenever boards are addressing strategic decisions and the company’s plan. CISOs should also help boards assess current and emerging risks and track the progress of the risk management programs. Finally, boards should hold private sessions with CISOs who will walk the directors through top risks, risk mitigation programs, and more using digestible and clearly articulated points.

Unfortunately, hiring skilled full-time in-house CISOs can be prohibitively expensive, especially for small and mid-sized businesses (“SMBs”). In addition, good CISOs are in high demand, making it hard to find, hire, and retain one. To deal with this, boards need to play an efficient oversight role and, in cases where they do not have the necessary expertise, have a constantly available source of expertise.

For SideChannel (OTCQB: SDCH), a company founded with the belief that all companies deserve top-tier security guidance at a manageable cost, this suggests a huge need for affordable cybersecurity-related expert services.

SideChannel has a team of expert virtual CISOs (“vCISOs”) and virtual Chief Privacy Officers (“vCPOs”) who help companies build resilient cybersecurity and privacy programs, respectively. Leveraging years of actual enterprise experience, SideChannel’s vCISOs provide clients with risk assessments that ensure cybersecurity compliance and help them develop a strategic vision, allocate resources, and create protocols to maintain an effective cybersecurity program.

And when called upon, SideChannel’s vCISOs can brief investors, boards, and company management. Speaking in a recent interview with Bell2Bell’s Stuart Smith (https://ibn.fm/Sz3fN), SideChannel CEO Brian Haugli attributed this to the trust built between its team of experts and its clients. In fact, the company has seen that trust increase over time. “Technically, we’re a third-party vendor, but we’re trusted so much that we are talking to the investors, maybe the private equity (‘PE’) team behind the company, and definitely the board in the leadership about what to do. We are also in front of our customers’ customers, telling them about the security posture because they are asking about it,” Haugli explained (https://ibn.fm/K4gKn).

It is common knowledge that addressing cyber risk is increasingly challenging for companies and their boards, as the threat environment becomes more complex. SideChannel is providing access to expertise through experienced vCISOs, a dependable and consistent source of critical information and experience, enabling companies and boards to understand the cyber environment, develop and track the progress of cybersecurity programs, and embed elements of cyber risk mitigation into all of their strategic decisions and plans. When it comes to cybersecurity, a few steps now can prevent a world of regret later.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Hillcrest Energy recently debuted the commercial prototype of its ZVS inverter technology
• The company revealed that its traction inverter can lead to powertrain efficiency gains of up to 13%; in practice, a gain of 1% could help drive a reduction in battery size by 2%
• In a recent investor briefing, Hillcrest forecasted that its inverter could help automotive OEM’s reduce material costs by close to $700 per electric vehicle
• Cost savings have increasingly become a focus of EV OEM’s, with vehicles selling for less than $55,000 eligible for a series of Government grants and rebates under the recently passed Inflation Reduction Act

In 2009, sales of electric vehicles in the United Kingdom touched a grand total of 55 cars (https://ibn.fm/4M9b2). Today, over 20 million EVs may be found on the road in distant corners of the globe, with the count expected to nearly quadruple to 77 million by 2025. The common denominator for these vehicles lays deep within their chassis. At their heart, each of those 77 million electric vehicles will contain a high-voltage battery, by far the vehicle’s most expensive component, and the fundamental driver of a veritable global race by battery manufacturers and automakers alike, to ethically source their materials and crank up production to meet exploding demand.

A recent study carried out by Reuters forecasts automakers will spend upwards of $1.2 trillion in developing and producing EVs through 2030 (https://ibn.fm/fLI1D). A significant proportion of that investment will be devoted to the production of better, more efficient batteries.

Electric luxury vehicle maker, Lucid Motors for instance produced just under 7,200 vehicles in 2022 – a figure commensurate to a mere two day of Tesla’s 2022 production. Nevertheless, the automaker has gained several plaudits for the record-setting, 830-kilometre driving range of its flagship Air Grand Touring Performance sedan. What makes that figure even more remarkable is that automakers using the same 2170 format battery cells commonly eke out a mere 267 mile of range on average – less than half of Lucid’s Air Grand sedan. A significant proportion of that outperformance may be directly attributed to Lucid’s highly efficient powertrain and inverter systems (https://ibn.fm/yTIHe).

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean technology company focused around developing transformative power conversion technologies, has recently announced the completion of its 800-volt, 250-kilowatt Zero Voltage Switching (“ZVS”) traction inverter commercial prototype (https://ibn.fm/hrFv0). In a series of tests, Hillcrest’s ZVS inverter was shown to generate powertrain efficiency improvements of up to 13%. To put that into perspective, current research suggests that every 1% improvement in efficiency can reduce battery size by 2%. If that were to hold true, then Hillcrest’s technological breakthrough effectively holds the potential to make EVs cheaper, lighter, and better performing (https://ibn.fm/sRwS3).

Hillcrest Energy have delved deeper into the potential efficiency gains which may be attained by their ground-breaking product; in a recent investor briefing, the company revealed that the ZVS traction inverter could generate up to $700 in material cost savings per electric vehicle for automotive OEM’s (https://ibn.fm/bEXmH). In effect and assuming a manufacturing run of 100,000 vehicles, an automaker could generate up to $70 million in cost savings – a figure which would further increase for vehicles using multiple motors and traction inverters (i.e., the Kia EV6 GT, Tesla Model S and BMW i4 M50 all operate using two or more electric motors).

Although increasing electric vehicles’ potential driving range whilst maintaining their battery size constant (or potentially, even downsizing them) has been the primary driver underpinning Hillcrest Energy’s developmental efforts thus far, driving down costs has not been far behind. Cost savings have increasingly become a priority within the electric vehicle manufacturing sector. Under the recently passed Inflation Reduction Act (“IRA”), potential EV buyers may be eligible for a series of tax credits when acquiring electric vehicles costing less than $55,000. Similarly, the IRA has introduced a new $4,000 EV tax credit for used electric vehicles which sell for under $25,000. As such, any automotive part which can assist an auto manufacturer in lowering its cost structure – and by extension, its average selling price, may ultimately be conducive to higher sales going forward.

For more information, visit the company’s website at www.HillcrestEnergy.tech.

NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• California-based sustainable bed and bath comfort brand Coyuchi Inc. has established its brand not only on the luxury of its products, but the organic sourcing of the textiles it uses
• Consumers increasingly are scrutinizing the sourcing of their home decor products in search of evidence they are friendly to earth’s climate and responsibly produced
• Coyuchi’s management team brings experience in corporate function and an enthusiasm for sustainability in the company’s sourcing and partnerships
• The company launched a Reg A+ investment offering last year that led to a capital raise topping $1 million

One significant driver in choosing fabrics for home decor these days is determining where they are sourced. “Homeowners, more than ever, are paying close attention to what their home fabrics are made of and where they have come from,” a recent report drawing on decorator’s insights states (https://ibn.fm/eKQUm).

Luxury bed, bath, and apparel product company Coyuchi devotes its corporate purpose to being “responsible beyond the thread” — using cotton and linen certified to the Global Organic Textile Standard (“GOTS”) respected as the most rigorous around the world, and extending beyond that to product use and recycling considerations.

“When Coyuchi was founded 30 years ago, the original founder — her goal was to bring organic cotton into the textile industry for home goods, and we’ve really taken that mission to heart,” Coyuchi President and CEO Eileen Mockus said during a recent interview with the Bell2Bell podcast (https://ibn.fm/GGr0I). “And (we) are finding ways to expand on it and continuing to look at the whole process of what we do.”

In addition to Sejal Solanki (Chief Marketing Officer), Marcus Chung (Chief Operating Officer), Gabriela Bermudez (Controller), and Priyadarshi Sinha (VP of Technology), Mockus leads an experienced team of sustainable fashion design enthusiasts.

Design Director Whitney Thornburg arrived in the industry from an education career where she developed and taught fashion design curriculum in sustainable practices and creating circular systems. After two years-long seasons working for a San Francisco clothing label, she joined Coyuchi in 2019.

Director of Sustainability and Sourcing Margot Lyons played a direct role in Coyuchi’s achievement of full circularity — a term describing the use of design, recycling, reuse, remanufacturing and refurbishment to create a closed loop system that eliminate waste and maximize the reuse of resources (https://ibn.fm/LEIn9). Lyons has been with the company for over a decade as it has built a wide reputation for luxury and responsibility, working with Coyuchi’s strategic partners to ensure the company’s standards for product sustainability are achieved. The effort led to Coyuchi’s first fully circular product — the Full Circle Recycled Cotton Blanket and Throw — in 2021.

Brand Marketing Director Julie Wells and Director of Operations Izzie Ali have similarly brought a drive for sustainable and eco-friendly business practices to the company with their arrivals during the past year, drawing on international educations as well as their experiences in North American industry.

Together, Coyuchi continues to maintain and expand their earth-friendly brand. The company’s Impact Report 2021 outlined Coyuchi’s goals for achieving Net Zero emissions by 2025 and becoming Net Positive by 2030, working under the direction of the Coyuchi Climate Council and in collaboration with a network of partners and non-profits around the world (https://ibn.fm/XxLqw).

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• DehydraTECH(TM) is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more
• The patented technology increases the speed of onset, bioavailability, brain absorption, and reduces drug administration costs
• Lexaria currently has multiple R&D programs – yielding successful results and further opportunities for additional study models

Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing bioavailability and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM) technology. DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more.

Most recently, a company announcement indicates that a just-completed DIAB-A22-1 diabetes study has produced at least three positive outcomes, including weight loss in obese diabetic-conditioned animals and shown improved triglyceride and cholesterol levels (https://ibn.fm/5micP). The animals tested in the study showed these dramatic changes in as few as three days when dosed with DehydraTECH-processed cannabidiol (“CBD”), aligned with other study work pointing to CBD’s known anti-inflammatory and antioxidant properties. Lexaria is pleased that relatively low dosages of DehydraTECH-CBD seem to support real improvements in the lab animals’ day-to-day health and find encouragement in the positive findings from its first diabetes study.

In addition to DIAB-A22-1, some of Lexaria’s previous R&D programs include:

• HYPER-A21-1 – a rodent study demonstrating significant enhancement in CBD delivery using DehydraTECH with more CBD delivered into the bloodstream and brain tissue
• HYPER-A21-2 – a rodent study demonstrating the strongest CBD absorption results ever recorded
• HYPER-H21-1 – Human clinical study evidencing a rapid and sustained drop in blood pressure with excellent tolerability using DehydraTECH-CBD
• HYPER-H21-2 – Human clinical Hypoxic Pulmonary Vasoconstriction study with evidence of up to a 23% decrease in blood pressure confirming a reduction in arterial stiffness
• HYPER-H21-3 – Human clinical Pulmonary Hypertension Clinical Study intended to support Lexaria’s plan to seek FDA approvals
• HYPER-H21-4 – Human clinical study exhibiting exceptional safety and tolerability with statistically significant evidence of lowered blood pressure in patients and showed great absorption levels and potential novel mechanism of action in reducing blood pressure
• VIRAL-C21-3 – In vitro screening assay completed using primate cell line, VERO-E6, determining that remdesivir and ebastine processed with DehydraTECH were effective in inhibiting the COVID-19 virus
• VIRAL-A20-2 – A rodent study showing a three-fold increase in oral delivery of anti-viral drugs
• VIRAL-MC21-1 – research concluded that DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity or change in chemical structure
• VIRAL-A20-3 – A rodent study demonstrating significant enhancement in anti-viral drug delivery using DehydraTECH-enabled Colchicine with possible benefits of treating COVID-19 and mRNA vaccine side effects
• NIC-A21-1 – DehydraTECH-oral nicotine delivery peaked in the bloodstream 10x and 20x faster than controls, with peak levels achieved 10x higher than controls
• PDE5-A21-1 – DehydraTECH-sildenafil delivered 74% more drug at 4 minutes than the control
• EPIL-A21-1 – DehydraTECH-CBD has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R)

Since 2014, Lexaria has been developing its patented DehydraTECH technology, which has yielded 28 granted patents and many more pending in countries worldwide. DehydraTECH’s evidenced benefits include the improved speed of onset, increased bioavailability, increased brain absorption, and reduced drug administration costs. As more research becomes available from Lexaria’s ongoing R&D programs, the company will provide updates.

Lexaria operates four subsidiary companies, focusing on different commercial opportunities in their respective industries:

• Lexaria Pharmaceutical Corp. investigates new products for hypertension, antiviral treatments, epilepsy, some pharmaceutical applications of nicotine and other drug classes
• Lexaria Nicotine LLC investigates oral non-combusted tobacco-derived nicotine product formats
• Lexaria Hemp Corp. pursues business-to-business opportunities with cannabinoids
• Lexaria Canpharm ULC operates a state-of-the-art Health Canada licensed laboratory capable of developing novel cannabinoid and other formulations for potential commercialization

Lexaria sub-licenses the company’s DehydraTECH technology for the delivery of fat-soluble active molecules and drugs.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• CNS recently enrolled the first patient in Spain in its ongoing global trial evaluating its lead drug candidate, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”)
• This milestone is the culmination of years of meticulous planning and execution
• The enrollment of this first patient follows the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma and neuro-oncology, just enrolled its first patient in Spain, marking a key milestone in its GBM clinical study. Considered a potentially pivotal global trial for the company, the study seeks to evaluate Berubicin, the company’s lead drug candidate, for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer.

In what the CEO, John Climaco, regarded as an “encouraging enrollment pace,” CNS is on track to conduct its planned interim analysis set for mid-2023. This recent enrollment of the first patient in Spain is a major highlight of this progress (https://ibn.fm/peyQi).

“We continue to rapidly build momentum with patient enrollment across our clinical trial sites in Europe,” noted Climaco.

“We sincerely appreciate the institutions, clinicians and staff that are contributing to the conduct of this trial, and are extremely grateful to the patients that choose to participate,” he added.

In 2007, a prior developer released partial results from its Phase 1 clinical trial of Berubicin among patients with primary CNS malignancies (https://ibn.fm/VwP1V). Results, which showed 44% of patients exhibiting a clinical response, demonstrated a durable complete response, along with a stable disease in heavily pretreated patients. Results from this study would set the stage for subsequent research by CNS, leading up to the dosing of the first subject in the US in the third quarter of 2021 and the first subject in Europe in November 2022 at a site in France (https://ibn.fm/weOO6).

The enrollment of the first patient in Spain affirms CNS’ commitment to the study and highlights the years of meticulous planning and execution which have culminated in this huge milestone for the company. It followed the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland, all in a move to better understand the treatment of recurrent GBM.

CNS believes Berubicin to be the first anthracycline to appear to cross the blood-brain barrier. While it has shown incredible potential in the treatment of brain-related illnesses, CNS is exploring its potential for the treatment of other diseases, including metastatic pancreatic and ovarian cancers, as well as CNS lymphomas. By doing so, it looks to tap into the growing brain tumor therapeutics market, which is expected to hit $3.4 billion by 2025, up from $2.25 billion in 2019.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP